PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070477
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070477
Oral Proteins and Peptides Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Oral Proteins and Peptides Market Size, Share, Growth and Industry Outlook (2025-2034)
The global oral proteins and peptides market was valued at USD 3.36 billion in 2025 and is projected to grow from USD 3.97 billion in 2026 to USD 9.17 billion by 2034, registering a CAGR of 11.03% during the forecast period. North America dominated the market with a 71.72% share in 2025, supported by the strong commercialization of oral peptide therapies, advanced healthcare infrastructure, and high adoption of innovative biologics.
Oral proteins and peptides represent a major advancement in drug delivery, enabling protein- and peptide-based therapies to be administered through tablets or capsules rather than injections. These therapies improve patient convenience, increase treatment adherence, and support earlier intervention in chronic disease management. The market is being driven by the commercial success of oral semaglutide, increasing physician acceptance of oral peptide therapies, growing investments in oral drug delivery technologies, and expanding development pipelines for oral insulin, oral PTH analogs, GLP-2 therapies, and obesity treatments.
Market Size and Forecast
- 2025 Market Size: USD 3.36 Billion
- 2026 Market Size: USD 3.97 Billion
- 2034 Market Size: USD 9.17 Billion
- CAGR (2026-2034): 11.03%
The increasing prevalence of diabetes, obesity, endocrine disorders, and metabolic diseases is expected to create sustained demand for oral peptide therapeutics throughout the forecast period.
Key Market Trends
Rising Preference for Non-Invasive Therapies
One of the most significant trends shaping the market is the growing preference for non-invasive treatment options. Patients increasingly favor oral medications over injectable therapies due to greater convenience, reduced needle anxiety, and improved adherence.
The approval of oral GLP-1 therapies has demonstrated strong commercial potential for oral biologics. In December 2025, Novo Nordisk received FDA approval for the Wegovy pill, further strengthening confidence in oral peptide-based weight management therapies.
Market Drivers
Increasing Prevalence of Chronic Diseases
The growing burden of chronic diseases continues to drive demand for oral proteins and peptides. Conditions such as type 2 diabetes, obesity, osteoporosis, and endocrine disorders require long-term treatment, making oral therapies highly attractive for both patients and healthcare providers.
According to WHO data, approximately 16% of adults globally were living with obesity in 2022. The expanding patient population creates significant opportunities for oral peptide therapies that offer efficacy comparable to injectable alternatives.
Growing Adoption of Oral GLP-1 Therapies
Commercial success of oral semaglutide products has encouraged pharmaceutical companies to invest heavily in next-generation oral biologics. Increasing physician confidence and patient acceptance are accelerating market expansion worldwide.
Market Restraints
High Development Costs
Developing oral peptide therapies remains expensive due to formulation complexity, absorption enhancement technologies, extensive clinical studies, and specialized manufacturing requirements. These factors increase development risks and create barriers for smaller biotechnology companies.
Low Bioavailability Challenges
Proteins and peptides are vulnerable to degradation within the gastrointestinal tract, making systemic absorption difficult. Ensuring consistent bioavailability remains one of the biggest scientific challenges for manufacturers.
Market Opportunities
Advances in Oral Drug Delivery Technologies
Innovations in absorption enhancers, protective coatings, and tablet delivery platforms are opening new growth opportunities. These technologies are enabling more biologics to be developed as oral formulations, expanding applications beyond diabetes into osteoporosis, obesity, and endocrine disorders.
In March 2026, Entera Bio submitted a streamlined Phase III protocol for its oral osteoporosis therapy EB613, highlighting the growing maturity of oral peptide delivery technologies.
Segment Analysis
By Drug Class
The GLP-1 Peptides segment dominated the market in 2025 due to strong commercial adoption and growing use in diabetes and obesity management. Novo Nordisk reported USD 3.4 billion in Rybelsus sales during 2025, reinforcing the segment's leadership.
The PTH Analogs segment is projected to record the fastest growth during the forecast period owing to promising osteoporosis treatment pipelines.
By Therapeutic Area
The Metabolic Disorders segment held the largest market share in 2025, driven by rising diabetes and obesity prevalence and increasing use of oral semaglutide therapies.
By Age Group
The Adult segment dominated the market as currently approved oral peptide therapies primarily target adult patients suffering from chronic diseases requiring long-term treatment.
By Formulation
The Tablets segment accounted for the largest share in 2025 due to ease of administration, patient convenience, and widespread physician acceptance.
By Distribution Channel
Retail Pharmacies & Drug Stores led the market in 2025 and are expected to account for approximately 71.5% of market share in 2026, supported by broad product availability and repeat prescription demand.
Regional Analysis
North America
North America remained the largest regional market, valued at USD 2.41 billion in 2025. Strong reimbursement systems, early product commercialization, and rapid adoption of oral GLP-1 therapies support regional dominance.
The U.S. market is projected to reach approximately USD 2.62 billion in 2026, representing around 66% of global revenues.
Europe
Europe is expected to grow at a CAGR of 15.66%, driven by increasing adoption of oral semaglutide therapies and supportive reimbursement policies.
Asia Pacific
Asia Pacific is projected to reach USD 0.46 billion in 2026, supported by large diabetic populations, improving healthcare access, and growing demand for innovative metabolic therapies.
Latin America and Middle East & Africa
These regions are expected to witness gradual growth due to increasing awareness, expanding healthcare infrastructure, and rising prevalence of diabetes and obesity.
Competitive Landscape
The market remains highly concentrated, with major companies focusing on commercialization, strategic collaborations, and pipeline expansion.
Key Companies
- Novo Nordisk (Denmark)
- Chiesi Group (Italy)
- EnteraBio Ltd. (Israel)
- Oramed Pharmaceuticals (U.S.)
- Protagonist Therapeutics Inc. (U.S.)
- Biocon (India)
- Rani Therapeutics (U.S.)
Leading players are investing in oral GLP-1 therapies, oral insulin programs, oral PTH analogs, and advanced drug delivery technologies to strengthen their market positions.
Recent Industry Developments
- September 2025: EnteraBio reported positive pharmacokinetic data for its oral GLP-2 tablet.
- June 2025: Protagonist Therapeutics nominated PN-477 as an obesity-focused oral peptide candidate.
- February 2025: Rani Therapeutics announced positive preclinical oral semaglutide delivery data using RaniPill technology.
- November 2024: Protagonist reported positive Phase III results for oral peptide candidate icotrokinra.
- June 2024: Rani Therapeutics partnered with ProGen for development of RT-114 oral obesity treatment.
Conclusion
The oral proteins and peptides market is entering a transformative growth phase as pharmaceutical companies continue shifting biologic therapies from injectable formats to convenient oral formulations. Growing chronic disease prevalence, strong commercial performance of oral GLP-1 therapies, technological advancements in drug delivery, and expanding development pipelines are expected to drive market expansion from USD 3.36 billion in 2025 to USD 9.17 billion by 2034. While challenges related to bioavailability and development costs remain, continued innovation and regulatory support are expected to create substantial opportunities for manufacturers and investors over the coming years.
Segmentation By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Region
By Drug Class * GLP-1 Peptides
- Somatostatin Analogs
- PTH Analogs
- GLP-2 Peptides
- Others
By Therapeutic Area * Metabolic Disorders
- Endocrine Disorders
- Others
By Age Group * Pediatric
- Adult
By Formulation * Tablets
- Others
By Distribution Channel * Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Specialty Pharmacies & Others
By Region * North America (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Pipeline Analysis, By Key Players
- 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.3. New Product Launches, By Key Players
- 4.4. Regulatory Scenario, By Key Countries/Regions
5. Global Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. GLP-1 Peptides
- 5.1.2. Somatostatin Analogs
- 5.1.3. PTH Analogs
- 5.1.4. GLP-2 Peptides
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 5.2.1. Metabolic Disorders
- 5.2.2. Endocrine Disorders
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adult
- 5.4. Market Analysis, Insights and Forecast - By Formulation
- 5.4.1. Tablets
- 5.4.2. Others
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospital Pharmacies
- 5.5.2. Retail Pharmacies & Drug Stores
- 5.5.3. Specialty Pharmacies & Others
- 5.6. Market Analysis, Insights and Forecast - Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. GLP-1 Peptides
- 6.1.2. Somatostatin Analogs
- 6.1.3. PTH Analogs
- 6.1.4. GLP-2 Peptides
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 6.2.1. Metabolic Disorders
- 6.2.2. Endocrine Disorders
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adult
- 6.4. Market Analysis, Insights and Forecast - By Formulation
- 6.4.1. Tablets
- 6.4.2. Others
- 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.5.1. Hospital Pharmacies
- 6.5.2. Retail Pharmacies & Drug Stores
- 6.5.3. Specialty Pharmacies & Others
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. GLP-1 Peptides
- 7.1.2. Somatostatin Analogs
- 7.1.3. PTH Analogs
- 7.1.4. GLP-2 Peptides
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 7.2.1. Metabolic Disorders
- 7.2.2. Endocrine Disorders
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adult
- 7.4. Market Analysis, Insights and Forecast - By Formulation
- 7.4.1. Tablets
- 7.4.2. Others
- 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.5.1. Hospital Pharmacies
- 7.5.2. Retail Pharmacies & Drug Stores
- 7.5.3. Specialty Pharmacies & Others
- 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Italy
- 7.6.5. Spain
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. GLP-1 Peptides
- 8.1.2. Somatostatin Analogs
- 8.1.3. PTH Analogs
- 8.1.4. GLP-2 Peptides
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 8.2.1. Metabolic Disorders
- 8.2.2. Endocrine Disorders
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adult
- 8.4. Market Analysis, Insights and Forecast - By Formulation
- 8.4.1. Tablets
- 8.4.2. Others
- 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.5.1. Hospital Pharmacies
- 8.5.2. Retail Pharmacies & Drug Stores
- 8.5.3. Specialty Pharmacies & Others
- 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.6.1. China
- 8.6.2. Japan
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. GLP-1 Peptides
- 9.1.2. Somatostatin Analogs
- 9.1.3. PTH Analogs
- 9.1.4. GLP-2 Peptides
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 9.2.1. Metabolic Disorders
- 9.2.2. Endocrine Disorders
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adult
- 9.4. Market Analysis, Insights and Forecast - By Formulation
- 9.4.1. Tablets
- 9.4.2. Others
- 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.5.1. Hospital Pharmacies
- 9.5.2. Retail Pharmacies & Drug Stores
- 9.5.3. Specialty Pharmacies & Others
- 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. GLP-1 Peptides
- 10.1.2. Somatostatin Analogs
- 10.1.3. PTH Analogs
- 10.1.4. GLP-2 Peptides
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 10.2.1. Metabolic Disorders
- 10.2.2. Endocrine Disorders
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adult
- 10.4. Market Analysis, Insights and Forecast - By Formulation
- 10.4.1. Tablets
- 10.4.2. Others
- 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies & Drug Stores
- 10.5.3. Specialty Pharmacies & Others
- 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.6.1. GCC
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Novo Nordisk
- 11.2.2. Chiesi Group
- 11.2.3. EnteraBio Ltd.
- 11.2.4. Oramed
- 11.2.5. Protagonist Therapeutics Inc.
- 11.2.6. Biocon
- 11.2.7. Rani Therapeutics
List of Tables
- Figure 1: Global Oral Proteins and Peptides Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
- Figure 2: Global Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025 & 2034
- Figure 3: Global Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025 & 2034
- Figure 4: Global Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025 & 2034
- Figure 5: Global Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025 & 2034
- Figure 6: Global Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025 & 2034
- Figure 7: Global Oral Proteins and Peptides Market Value Share (%), By Region, 2025 & 2034
- Figure 8: North America Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 9: North America Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
- Figure 10: North America Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
- Figure 11: North America Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
- Figure 12: North America Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 13: North America Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
- Figure 14: North America Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
- Figure 15: North America Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
- Figure 16: North America Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 17: North America Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
- Figure 18: North America Oral Proteins and Peptides Market Value (USD billion), by Country, 2025 & 2034
- Figure 19: North America Oral Proteins and Peptides Market Value Share (%), by Country, 2025
- Figure 20: Europe Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 21: Europe Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
- Figure 22: Europe Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
- Figure 23: Europe Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
- Figure 24: Europe Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 25: Europe Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
- Figure 26: Europe Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
- Figure 27: Europe Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
- Figure 28: Europe Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 29: Europe Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
- Figure 30: Europe Oral Proteins and Peptides Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 31: Europe Oral Proteins and Peptides Market Value Share (%), by Country/ Sub-region, 2025
- Figure 32: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 33: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
- Figure 34: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
- Figure 35: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
- Figure 36: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 37: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
- Figure 38: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
- Figure 39: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
- Figure 40: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 41: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
- Figure 42: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 43: Asia Pacific Oral Proteins and Peptides Market Value Share (%), by Country/ Sub-region, 2025
- Figure 44: Latin America Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 45: Latin America Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
- Figure 46: Latin America Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
- Figure 47: Latin America Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
- Figure 48: Latin America Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 49: Latin America Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
- Figure 50: Latin America Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
- Figure 51: Latin America Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
- Figure 52: Latin America Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 53: Latin America Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
- Figure 54: Latin America Oral Proteins and Peptides Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 55: Latin America Oral Proteins and Peptides Market Value Share (%), by Country/ Sub-region, 2025
- Figure 56: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 57: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
- Figure 58: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
- Figure 59: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
- Figure 60: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 61: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
- Figure 62: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
- Figure 63: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
- Figure 64: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 65: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
- Figure 66: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), by Country/ Sub-region, 2025
- Figure 68: Global Oral Proteins and Peptides Market Share (%), by Company, 2025
